{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:49:45Z","timestamp":1761094185325,"version":"build-2065373602"},"reference-count":32,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2013,12,13]],"date-time":"2013-12-13T00:00:00Z","timestamp":1386892800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100012246","name":"Priority Academic Program Development of Jiangsu Higher Education Institutions","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012246","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2014,2]]},"abstract":"<jats:sec><jats:title>Study Objective<\/jats:title><jats:p>To investigate the associations of <jats:italic><jats:styled-content style=\"fixed-case\">NOS<\/jats:styled-content>1<jats:styled-content style=\"fixed-case\">AP<\/jats:styled-content><\/jats:italic> rs12742393 polymorphism with the risk of type 2 diabetes mellitus (T2<jats:styled-content style=\"fixed-case\">DM<\/jats:styled-content>) and repaglinide therapeutic efficacy in Chinese patients with T2<jats:styled-content style=\"fixed-case\">DM<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Prospective case\u2010control study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>Academic medical center.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients<\/jats:title><jats:p>A total of 300 patients with T2<jats:styled-content style=\"fixed-case\">DM<\/jats:styled-content> and 200 healthy volunteers were enrolled to identify <jats:italic><jats:styled-content style=\"fixed-case\">NOS<\/jats:styled-content>1<jats:styled-content style=\"fixed-case\">AP<\/jats:styled-content><\/jats:italic> rs12742393 genotypes using the polymerase chain reaction\u2013restriction fragment length polymorphism assay. Eighty\u2010four patients with various genotypes were randomly selected to receive oral repaglinide as a single\u2010agent therapy (3\u00a0mg\/day) for 8\u00a0weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Measurements and Main Results<\/jats:title><jats:p>Anthropometric measurements and fasting plasma glucose (FPG), postprandial plasma glucose, hemoglobin A<jats:sub>1c<\/jats:sub>, fasting serum insulin (FINS), postprandial serum insulin, homeostasis model assessment for insulin resistance (HOMA\u2010IR), triglyceride, total cholesterol, low\u2010density lipoprotein\u2010cholesterol, and high\u2010density lipoprotein\u2010cholesterol tests were obtained before and after repaglinide treatment. The risk C allelic frequency of <jats:italic>NOS1AP<\/jats:italic> rs12742393 was higher in patients with T2DM than in healthy volunteers (p&lt;0.001). Patients with T2DM and genotypes AA and AC at <jats:italic>NOS1AP<\/jats:italic> rs12742393 had a significant reduction in FPG (mmol\/l) compared with those with genotype CC (p&lt;0.01). Patients with CC homozygotes and AC heterozygotes had a greater increase in FINS (<jats:styled-content style=\"fixed-case\">mU<\/jats:styled-content>\/l) than those with wild\u2010type AA (p&lt;0.05). In addition, the carriers of genotype CC at <jats:italic>NOS1AP<\/jats:italic> rs12742393 had higher differential values of HOMA\u2010IR compared with genotypes AC and AA carriers (p&lt;0.001). The effects of repaglinide treatment on FPG (p&lt;0.01), FINS (p&lt;0.05) and HOMA\u2010IR (p&lt;0.001) were reduced in patients with T2DM carrying the <jats:italic>NOS1AP<\/jats:italic> rs12742393 risk C allele compared with the AA genotype carriers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The <jats:italic><jats:styled-content style=\"fixed-case\">NOS<\/jats:styled-content>1<jats:styled-content style=\"fixed-case\">AP<\/jats:styled-content><\/jats:italic> rs12742393 polymorphism is associated with therapeutic efficacy of repaglinide in Chinese T2<jats:styled-content style=\"fixed-case\">DM<\/jats:styled-content> patients.<\/jats:p><\/jats:sec>","DOI":"10.1002\/phar.1379","type":"journal-article","created":{"date-parts":[[2013,12,13]],"date-time":"2013-12-13T07:34:41Z","timestamp":1386920081000},"page":"131-139","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Effects of <i><scp>NOS<\/scp>1<scp>AP<\/scp><\/i> rs12742393 Polymorphism on Repaglinide Response in Chinese Patients with Type 2 Diabetes Mellitus"],"prefix":"10.1002","volume":"34","author":[{"given":"Tao","family":"Wang","sequence":"first","affiliation":[{"name":"Key Laboratory of New Drugs and Clinical Application Xuzhou Medical College Xuzhou China"},{"name":"Department of Pharmacy the Affiliated Hospital of Xuzhou Medical College Xuzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy the Affiliated Hospital of Xuzhou Medical College Xuzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong\u2010Mei","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Pharmacy the Affiliated Hospital of Xuzhou Medical College Xuzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin\u2010Fang","family":"Song","sequence":"additional","affiliation":[{"name":"Key Laboratory of New Drugs and Clinical Application Xuzhou Medical College Xuzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Lu","sequence":"additional","affiliation":[{"name":"Key Laboratory of New Drugs and Clinical Application Xuzhou Medical College Xuzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy the Affiliated Hospital of Xuzhou Medical College Xuzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Key Laboratory of New Drugs and Clinical Application Xuzhou Medical College Xuzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Guo","sequence":"additional","affiliation":[{"name":"Key Laboratory of New Drugs and Clinical Application Xuzhou Medical College Xuzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology the Affiliated Hospital of Xuzhou Medical College Xuzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao\u2010Xing","family":"Yin","sequence":"additional","affiliation":[{"name":"Key Laboratory of New Drugs and Clinical Application Xuzhou Medical College Xuzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,12,13]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.208"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature05616"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.4.5.529"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1998.tb03137.x"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1753-0407.2012.00225.x"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.242"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-010-0882-6"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.01.018"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(03)00228-5"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.110.036921"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0896-6273(00)80439-0"},{"key":"e_1_2_7_13_1","doi-asserted-by":"crossref","first-page":"700","DOI":"10.4414\/smw.2007.11950","article-title":"Insulin resistance in mice lacking neuronal nitric oxide synthase is related to an alpha\u2010adrenergic mechanism","volume":"137","author":"Turini P","year":"2007","journal-title":"Swiss Med Wkly"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.50.6.1311"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.200301063"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI3030"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.49.5.684"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-008-1143-4"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-009-1608-0"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-009-1594-2"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2350-9-118"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.2337\/db09-0081"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1745-7254.2007.00643.x"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2004.08.014"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2005.04.005"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpb.2005.05.048"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.55.04.06.db05-1532"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e328300e8c5"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2011.06.014"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/aps.2010.25"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.2337\/db07-0056"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-010-1833-6"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.14.1688"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1379","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1379","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.1379","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:30:43Z","timestamp":1761057043000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.1379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,13]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["10.1002\/phar.1379"],"URL":"https:\/\/doi.org\/10.1002\/phar.1379","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2013,12,13]]},"assertion":[{"value":"2013-12-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}